BCR-ABL-negative chronic myeloid leukemia

Current Hematologic Malignancy Reports

Volumn 2, Issue 2, 2007, Pages 75-82

  Burgstaller, Sonja ^b   Reiter, Andreas ^b   Cross, Nicholas C P ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CD135 ANTIGEN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; JANUS KINASE 2; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE; RAS PROTEIN;

CANCER RESEARCH; CARCINOGENESIS; CELL STRUCTURE; CHROMOSOME 22; CHROMOSOME 4Q; CHROMOSOME 8P; CHROMOSOME 9; CHROMOSOME ABERRATION; CHROMOSOME DUPLICATION; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; DISEASE CLASSIFICATION; ENZYME ACTIVATION; FUSION GENE; HUMAN; KARYOTYPING; MOLECULAR GENETICS; MUTAGENESIS; MYELOPROLIFERATIVE DISORDER; POINT MUTATION; REVIEW; SIGNAL TRANSDUCTION; WORLD HEALTH ORGANIZATION;

AGED; ANEUPLOIDY; ENZYME ACTIVATION; HUMANS; LEUKEMIA, MYELOID, CHRONIC, ATYPICAL, BCR-ABL NEGATIVE; MIDDLE AGED; MUTATION; ONCOGENE PROTEINS, FUSION; PROTEIN KINASES; RISK FACTORS; SIGNAL TRANSDUCTION; TRANSLOCATION, GENETIC;

EID: 34248524663     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-007-0011-5     Document Type: Review

References (49)

1. Vardiman JW, Harris NL, Brunnmg RD: The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002, 100:2292-2302.
2. Chase A, Huntly BJ, Cross NCP: Cytogenetics of chronic myeloid leukaemia. Best Bract Res Clin Haematol 2001, 14:553-571.
3. Onida F, Ball G, Kantarjian HM, et al.: Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia. Cancer 2002, 95:1673-1684.
4. Steer FJ, Cross NCP: Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor-β. Acta Haematol 2002, 107:113-122.
5. Baxter EJ, Hochhaus A, Bolufer P, et al.: The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. Hum Mol Genet 2002, 11:1391-1397.
6. Trempat P, Villalva C, Laurent G, et al.: Chronic myeloproliferative disorders with rearrangement of the platelet-derived growth factor alpha receptor: A new clinical target for STI571/Glivec. Oncogene 2003, 22:5702-5706.
7. Cools J, DeAngelo DJ, Gotlib J, et al.: A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003, 348:1201-1214.
8. Griffin JH, Leung J, Bruner RJ, et al.: Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci U S A 2003, 100:7830-7835.
9. Score J, Curtis C, Waghorn K, et al.: Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Leukemia 2006, 20:827-832.
10. Pardanani A, Ketterling RP, Li CY, et al.: FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res 2006, 30:965-970.
11. Walz C, Curtis C, Schnittger S, et al.: Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene. Genes Chromosomes Cancer 2006, 45:950-956.
12. • Stover EH, Chen J, Folens C, et al.: Activation of FIP1L1-PDGFRα requires disruption of the juxtamembrane domain of PDGFRα and is FIP1L1-independent. Proc Natl Acad Sci U S A 2006, 103:8078-8083. Molecular analysis of PDGFR fusions reveals a new means of kinase activation in MPDs.
13. Wilkinson K, Velloso ER, Lopes LF, et al.: Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib. Blood 2003, 102:4187-4190.
14. Morerio C, Acquila M, Rosanda C, et al.: HCMOGT-1 is a novel fusion partner to PDGFRB in juvenile myelomonocytic leukemia with t(5;17)(q33;p11.2). Cancer Res 2004, 64:2649-2651.
15. Vizmanos JL, Novo FJ, Román JP, et al.: NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder. Cancer Res 2004, 64:2673-2676.
16. Levine RL, Wadleigh M, Sternberg DW, et al.: KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q.33;q32). Leukemia 2005, 19:27-30.
17. Grand FH, Burgstaller S, Kuhr T, et al.: p53-Binding protein 1 is fused to the platelet-derived growth factor receptor beta in a patient with a t(5;15)(q33;q22) and an imatinib-responsive eosinophilic myeloproliferative disorder. Cancer Res 2004, 64:7216-7219.
18. Rosati R, La Starza R, Luciano L, ct al.: TPM3/PDGFRB fusion transcript and its reciprocal in chronic eosinophilic leukaemia. Leukemia 2006, 20:1623-1624.
19. Abe A, Emi N, Tanimoto M, et al.: Fusion of the platelet-derived growth factor receptor beta to a novel gene CEV14 in acute myelogenous leukemia after clonal evolution. Blood 1997, 90:4271-4277.
20. • David M, Cross NCP, Burgstaller S, et al.: Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood 2007, 109:61-64. Largest series of PDGFRB-rearranged cases treated with imatinib.
21. Gotlib J: Molecular classification and pathogenesis of eosinophilic disorders: 2005 update. Acta Haematol 2005, 114:7-25.
22. Vannier JP, Bizet M, Bastard C, et al.: Simultaneous occurrence of a T-cell lymphoma and a chronic myelogenous leukemia with an unusual karyotype. Leuk Res 1984, 8:647-657.
23. Macdonald D, Reiter A, Cross NCP: The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1 [review]. Acta Haematol 2002, 107:101-107.
24. Inhorn RC, Aster JC, Roach SA, et al.: A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity. Blood 1995, 85:1881-1887.
25. Guasch G, Popovici C, Mugneret F, et al.: Endogenous retroviral sequence is fused to FGFR1 kinase in the 8p12 stem-cell myeloproliferative disorder with t(8;19)(p12;q1.3.3). Blood 2003, 101:286-288.
26. Belloni E, Trubia M, Gasparini P, et al.: 8p11 myeloproliferative syndrome with a novel t(7;8) translocation leading to fusion of the FGFR1 and TIF1 genes. Genes Chromosomes Cancer 2005, 42:320-325.
27. Grand EK, Grand FH, Chase AJ, et al.: Identification of a novel gene, FGFR1OP2, fused to FGFR1 in the 8p11 myeloproliferative syndrome. Genes Chromosomes Cancer 2003, 40:78-83.
28. Walz C, Chase A, Schoch C, et al.: The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1. Leukemia 2005, 19:1005-1009.
29. Demiroglu A, Steer EJ, Heath C, et al.: The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. Blood 2001, 98:3778-3783.
30. Vizmanos JL, Hernandez R, Vidal MJ, et al.: Clinical variability of patients with the t(6;8)(q27;p12) and FGFR1OP-FGFR1 fusion: two further cases. Hematol J 2004, 5:534-537.
31. • Roumiantsev S, Krause DS, Neumann CA, et al.: Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations. Cancer Cell 2004, 5:287-298.
32. Lin P, Jones D, Medeiros LJ, et al.: Activating FLT3 mutations are detectable in chronic and blast phase of chronic myeloproliferative disorders other than chronic myeloid leukemia. Am J Clin Pathol 2006, 126:530-533.
33. Vu HA, Xinh PT, Masuda M, et al.: FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation. Leukemia 2006, 20:1414-1421.
34. Lacronique V, Boureux A, Valle VD, et al.: A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997, 278:1309-1312.
35. Peeters P, Raynaud SD, Cools J, et al.: Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 1997, 90:2535-2540.
36. Reiter A, Walz C, Watmore A, et al.: The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res 2005, 65:2662-2667.
37. Griesinger F, Hennig H, Hillmer F, et al.: A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia. Genes Chromosomes Cancer 2005, 44:329-333.
38. Ries LAG, Eisner MP, Kosary CL: SEER Cancer Statistic Review, 1975-2000. Bethesda, MD: National Cancer Institute; 2003.
39. Jones AV, Kreil S, Zoi K, et al.: Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005, 106:2162-2168.
40. Steensma DP, Dewald GW, Lasho TL, et al.: The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood 2005, 106:1207-1209.
41. Jelinek J, Oki Y, Gharibyan V, et al.: JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 2005, 106:3370-3373.
42. Gu TL, Goss VL, Reeves C, et al.: Phosphotyrosine profiling identifies the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemia. Blood 2006, 108:4202-4204.
43. Kurzrock R, Bueso-Ramos CE, Kantarjian H, et al.: BCR rearrangement-negative chronic myelogenous leukemia revisited. J Clin Oncol 2001, 19:2915-2926.
44. Chen J, DeAngelo DJ, Kutok JL, et al.: PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci U S A 2004, 101:14479-14484.
45. Talpaz M, Shah NP, Kantarjian H, et al.: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006, 354:2531-2541.
46. Kantarjian H, Giles F, Wunderle L, et al.: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006, 354:2542-2551.
47. Stover EH, Chen J, Lee BH, et al.: The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRβ and FIP1L1-PDGFRα in vitro and in vivo. Blood 2005, 106:3206-3213.
48. Lierman E, Folens C, Stover EH, et al.: Sorafenib (BAY 43-9006) is a potent inhibitor of FIP1L1-PDGFRA and the imatinib resistant FIP1L1-PDGFRA T674I mutant. Blood 2006, 108:1374-1376.
49. • Tefferi A, Gilliland G: Classification of chronic myeloid disorders: From Dameshek towards a semi-molecular system. Best Bract Res Clin Haematol 2006, 19:365-385.